Euroscicon, United Kingdom
16 February 2012
9:00 – 9:45 Registration 9:45 – 10:00 Introduction by the Chair: Professor Christopher J. Hewitt, Loughborough University, UK 10:00 – 10:20 Skeletal Stem Cells – Bridging the Gap in Bone Regeneration from Cell Biology to Clinical Translation Professor Richard OC Oreffo, University of Southampton, UK (morning speaking slot) 10:20 – 10:40 Translating Research Into Viable Clinical Treatments. How to build on 60 years of patient focused clinical delivery Dr Simon Ellison, National Blood Service, UK (morning speaking slot) The criticality of managing the process from consent to patient. • Utilising open innovation partnerships can deliver treatments and revenue. • How to generate patient focused manufacturing and scale up. • Accessing validated national cold supply chains. 10:40 – 11:00 The future potential of cellular immunotherapy’s Dr Mark Cobbold, The University of Birmingham¸UK . 11:00 – 11:30 Speakers’ photo then mid-morning break and trade show 11:30 – 11:50 Improving the yield of pluripotent stem cell differentiation processess Dr Farlan Veraitch, Department of Biochemical Engineering, University College London, UK 11:50 – 12:10 Scaling Red Blood Cell Manufacture from Cord Blood and Placenta Derived CD34+ Haematopoietic Stem Cells Dr Robert Thomas, Senior Lecturer, Associate Director EPSRC Centre for Innovative Manufacturing in Regenerative Medicine The technology to expand and differentiate stem cells from human umbilical cord blood will potentially underpin the manufacture of a number of therapeutic cellular products, including erythrocytes and platelets. Such technology will overcome the logistical limitations associated with sourcing short shelf-life and disease screened voluntary blood donations. However, these cell products pose significant challenges in the development of economically scalable production systems and processes that are capable of consistent delivery of clinical quality cells. As part of an international and multidisciplinary consortium of engineers and cell biologists led by Celgene Cellular Therapeutics, we have established key challenges and mitigating strategies for the production of erythrocytes at large scale from umbilical cord and placenta derived CD34+ cells. We have demonstrated a multi-stage expansion and differentiation process that integrates both established and novel technologies and cytokine supplementation schedules to consistently achieve high production densities of erythroid cells. We have further employed a new millilitre scale precision process development platform (AMBR, TAP Biosystems) to rigorously characterise critical elements of the production environment and identify factors determining cell expansion and quality (assessed through development of multiple erythroid markers including CD71, CD235a and Haemoglobin) and to reduce process cost. In the near future the consortium anticipates further optimisation of the bioprocess and automated integration of downstream processing to facilitate clinical-scale production of a therapeutically effective red blood cell like product. The process development and control learning, and the key parameter ranges established, are likely to be transferable to other development programmes for regenerative cell products. 12:10– 12:30 Talk to be confirmed Dr Annette Meeson, Institute of Human Genetics, Newcastle University, International Centre for Life, UK 12:30 – 13:30 Lunch and trade show 13:30 – 14:30 Question and Answer Session Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day 14:30 – 15:00 Oral presentations 15:00 - 15:30 Afternoon Tea/Coffee and trade show 15:30 – 15:50 Regulation of Regenerative Medicine Products Ms Alison Wilson, CellData Services, UK • Outline of the Advanced Therapy Medicinal Products Regulation • Other relevant legislation • Major regulatory issues in progressing from the lab to the clinic 15:50 – 16:10 Talk to be confirmed Professor Julian B Chaudhuri, Professor of Biochemical & Biomedical Engineering, Centre for Regenerative Medicine, Department of Chemical Engineering, University of Bath, UK 16:10 – 16:30 Chairman’s summing up
|